申请人:NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
公开号:US20160060235A1
公开(公告)日:2016-03-03
An object of the present invention is to provide a novel therapeutic agent for a patient with type 2 diabetes, a cause of which is the abnormal synthesis of insulin attributed to the abnormal modification of tRNA
Lys
(UUU) in pancreatic β cells having Cdkal1 gene mutation. The present inventors have used (1) a screening system using
E. coli
in which correct translation into luciferase requires frameshift resulting from mistranslation during protein translation, (2) a screening system using the pancreatic islet of Langerhans isolated from a pancreatic β cell-specific Cdkal1-deficient mouse, and (3) a screening system using a pancreatic β cell-specific Cdkal1-deficient mouse, and found that a compound represented by any of the following formulas (I) to (III) can serve as a therapeutic agent for a patient with type 2 diabetes with Cdkal1 gene mutation resulting in the reduced ability to secrete insulin.
本发明的一个目的是为2型糖尿病患者提供一种新型治疗剂,其原因是由于胰岛素的异常合成归因于胰岛β细胞中tRNALys(UUU)的异常修饰,其具有Cdkal1基因突变。本发明者已经使用了(1)使用大肠杆菌的筛选系统,其中正确的翻译成荧光酶需要在蛋白质翻译过程中由于错误翻译而导致的移码,(2)使用从胰岛β细胞特异性Cdkal1缺陷小鼠中分离的Langerhans胰岛的筛选系统,以及(3)使用胰岛β细胞特异性Cdkal1缺陷小鼠的筛选系统,并发现以下任一式(I)至(III)所代表的化合物可以作为一种治疗剂,用于具有Cdkal1基因突变且导致胰岛素分泌能力降低的2型糖尿病患者。